These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34932447)

  • 1. Extensively Drug-Resistant Carbapenemase-Producing Pseudomonas aeruginosa and Medical Tourism from the United States to Mexico, 2018-2019.
    Kracalik I; Ham DC; McAllister G; Smith AR; Vowles M; Kauber K; Zambrano M; Rodriguez G; Garner K; Chorbi K; Cassidy PM; McBee S; Stoney RJ; Moser K; Villarino ME; Zazueta OE; Bhatnagar A; Sula E; Stanton RA; Brown AC; Halpin AL; Epstein L; Walters MS;
    Emerg Infect Dis; 2022 Jan; 28(1):51-61. PubMed ID: 34932447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difficult-to-treat (DTR)
    Vega AD; DeRonde K; Jimenez A; Piazza M; Vu C; Martinez O; Rojas LJ; Marshall S; Yasmin M; Bonomo RA; Abbo LM
    Antimicrob Agents Chemother; 2024 May; 68(5):e0147423. PubMed ID: 38602418
    [No Abstract]   [Full Text] [Related]  

  • 3. Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears.
    Grossman MK; Rankin DA; Maloney M; Stanton RA; Gable P; Stevens VA; Ewing T; Saunders K; Kogut S; Nazarian E; Bhaurla S; Mephors J; Mongillo J; Stonehocker S; Prignano J; Valencia N; Charles A; McNamara K; Fritsch WA; Ruelle S; Plucinski CA; Sosa LE; Ostrowsky B; Ham DC; Walters MS;
    Clin Infect Dis; 2024 Jul; 79(1):6-14. PubMed ID: 38315890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem-Resistant Pseudomonas aeruginosa.
    Hu Y; Qing Y; Chen J; Liu C; Lu J; Wang Q; Zhen S; Zhou H; Huang L; Zhang R
    Microbiol Spectr; 2021 Dec; 9(3):e0134421. PubMed ID: 34817230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.
    Karampatakis T; Antachopoulos C; Tsakris A; Roilides E
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1211-1220. PubMed ID: 29644540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notes from the Field: Verona Integron-Encoded Metallo-β-Lactamase-Producing Carbapenem-Resistant Pseudomonas aeruginosa Infections in U.S. Residents Associated with Invasive Medical Procedures in Mexico, 2015-2018.
    Kracalik I; Ham C; Smith AR; Vowles M; Kauber K; Zambrano M; Rodriguez G; Garner K; Chorbi K; Cassidy PM; McBee S; Stoney R; Brown AC; Moser K; Villarino ME; Walters MS
    MMWR Morb Mortal Wkly Rep; 2019 May; 68(20):463-464. PubMed ID: 31120867
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-{beta}-lactamase in a teaching hospital in southern Brazil.
    Zavascki AP; Gaspareto PB; Martins AF; Gonçalves AL; Barth AL
    J Antimicrob Chemother; 2005 Dec; 56(6):1148-51. PubMed ID: 16239284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenemase-producing Pseudomonas aeruginosa from central Greece: molecular epidemiology and genetic analysis of class I integrons.
    Liakopoulos A; Mavroidi A; Katsifas EA; Theodosiou A; Karagouni AD; Miriagou V; Petinaki E
    BMC Infect Dis; 2013 Oct; 13():505. PubMed ID: 24168643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Carbapenem Resistance Mechanisms and Its Association with Pseudomonas aeruginosa Infections in the Northwest of Iran.
    Akhi MT; Khalili Y; Ghotaslou R; Yousefi S; Kafil HS; Naghili B; Sheikhalizadeh V
    Microb Drug Resist; 2018 Mar; 24(2):126-135. PubMed ID: 28654368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
    Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and virulence of VIM-4 metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from burn patients in eastern Algeria.
    Meradji S; Barguigua A; Bentakouk MC; Nayme K; Zerouali K; Mazouz D; Chettibi H; Timinouni M
    Burns; 2016 Jun; 42(4):906-18. PubMed ID: 27156788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying bla
    PÉrez-VÁzquez M; Sola-Campoy PJ; Zurita ÁM; Ávila A; GÓmez-Bertomeu F; SolÍs S; LÓpez-Urrutia L; GÓnzalez-BarberÁ EM; Cercenado E; Bautista V; Lara N; Aracil B; Oliver A; Campos J; Oteo-Iglesias J;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106026. PubMed ID: 32450200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of Imipenem-Resistant Pseudomonas aeruginosa Clinical Isolates from Egypt Coharboring VIM and IMP Carbapenemases.
    El-Domany RA; Emara M; El-Magd MA; Moustafa WH; Abdeltwab NM
    Microb Drug Resist; 2017 Sep; 23(6):682-686. PubMed ID: 28085553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. aeruginosa high-risk clones with VIM-5- and IMP-7-type carbapenemases in a tertiary hospital.
    Çekin ZK; Dabos L; Malkoçoğlu G; Fortineau N; Bayraktar B; Iorga BI; Naas T; Aktaş E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115174. PubMed ID: 32980808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. bla
    Aruhomukama D; Najjuka CF; Kajumbula H; Okee M; Mboowa G; Sserwadda I; Mayanja R; Joloba ML; Kateete DP
    BMC Infect Dis; 2019 Oct; 19(1):853. PubMed ID: 31619192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cluster of Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa Among Patients in an Adult Intensive Care Unit - Idaho, 2021-2022.
    Cahill ME; Jaworski M; Harcy V; Young E; Ham DC; Gable P; Carter KK
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(31):844-846. PubMed ID: 37535466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem-resistant Pseudomonas aeruginosa strains from a Spanish hospital: characterization of metallo-beta-lactamases, porin OprD and integrons.
    Rojo-Bezares B; Estepa V; Cebollada R; de Toro M; Somalo S; Seral C; Castillo FJ; Torres C; Sáenz Y
    Int J Med Microbiol; 2014 May; 304(3-4):405-14. PubMed ID: 24594145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.